Associations of sNfL with clinico-radiological measures in a large MS population.
Associations of sNfL with clinico-radiological measures in a large MS population.
复制标题
DOI：
10.1002/acn3.51704
复制
发表时间：
2023-01
影响因子：
5.3
通讯作者：
Calabresi, Peter A.
中科院分区：
文献类型：
--
作者：
Sotirchos, Elias S.;Fitzgerald, Kathryn C.;Singh, Carol M.;Smith, Matthew D.;Reyes-Mantilla, Maria;Hersh, Carrie M.;Hyland, Megan H.;Canissario, Ryan;Simmons, Sarah B.;Arrambide, Georgina;Montalban, Xavier;Comabella, Manuel;Naismith, Robert T.;Qiao, Min;Krupp, Lauren B.;Nicholas, Jacqueline A.;Akgun, Katja;Ziemssen, Tjalf;Rudick, Richard;Fisher, Elizabeth;Bermel, Robert A.;Mowry, Ellen M.;Calabresi, Peter A.
血清神经丝轻链（sNfL）的评价是sNfL用于临床实践的关键步骤，该评价是在真实的MS人群中使用广泛使用的平台上使用高通量测定法进行的。多发性硬化症合作伙伴推进技术和健康解决方案（MS PATHS）是美国和欧洲的医疗保健机构网络，在常规诊所访视期间收集标准化的临床/成像数据和生物标本。使用高通量、可扩展的免疫测定法，在6974名MS和201名健康对照（HC）参与者中测量sNfL。在1238名MS参与者（17.8%）中发现sNfL水平随年龄升高（sNfL-E）。与sNfL-E相关的因素包括男性、年龄较小、疾病进展亚型、糖尿病、肾功能受损和主动吸烟。较高的体重指数（BMI）与sNfL升高的可能性较低相关。采用疾病改善治疗的积极治疗与sNfL-E的发生率较低相关。患有sNfL-E的MS受试者表现出更差的神经功能（患者报告的残疾、行走速度、手动灵活性和认知处理速度）、更低的脑实质分数和更高的T2病变体积。纵向分析显示，sNfL-E参与者的全脑萎缩短期发生率加快，新发T2病变的几率更高，尽管与HC相比，有或没有sNfL-E的MS参与者的全脑萎缩发生率更快。在将年龄标准sNfL Z评分作为连续变量进行检查的分析中，结果一致。sNfL升高与MS的临床残疾、炎性疾病活动和全脑萎缩相关，但解释需要考虑合并症，包括肾功能受损、糖尿病和吸烟。
Evaluation of serum neurofilament light chain (sNfL), measured using high‐throughput assays on widely accessible platforms in large, real‐world MS populations, is a critical step for sNfL to be utilized in clinical practice. Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high‐throughput, scalable immunoassay. Elevated sNfL levels for age (sNfL‐E) were found in 1238 MS participants (17.8%). Factors associated with sNfL‐E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease‐modifying therapy was associated with lower odds of sNfL‐E. MS participants with sNfL‐E exhibited worse neurological function (patient‐reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short‐term rates of whole brain atrophy in sNfL‐E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL‐E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age‐normative sNfL Z‐scores as a continuous variable. Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking.
登录
查看更多内容
影响因子：
2.6
作者：
Learmonth YC;Motl RW;Sandroff BM;Pula JH;Cadavid D
通讯作者：
Cadavid D
DOI：
10.1056/nejmra1401483
发表时间：
2018-01-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Reich DS;Lucchinetti CF;Calabresi PA
通讯作者：
Calabresi PA
影响因子：
11
作者：
Disanto, Giulio;Adiutori, Rocco;Ramagopalan, Sreeram V.
通讯作者：
Ramagopalan, Sreeram V.
影响因子：
4.6
作者：
Altmann P;Leutmezer F;Zach H;Wurm R;Stattmann M;Ponleitner M;Petzold A;Zetterberg H;Berger T;Rommer P;Bsteh G
通讯作者：
Bsteh G
影响因子：
5.1
作者：
Rao, S. M.;Galioto, R.;Rudick, R. A.
通讯作者：
Rudick, R. A.